Metsera (NASDAQ:MTSR) Issues Earnings Results

Metsera (NASDAQ:MTSR) posted its quarterly earnings results on Wednesday. The company reported ($3.52) earnings per share for the quarter, Zacks reports.

Metsera Trading Up 6.8 %

Shares of Metsera stock opened at $30.01 on Friday. Metsera has a 12-month low of $23.08 and a 12-month high of $32.81.

Analysts Set New Price Targets

Several equities research analysts have recently commented on the company. Cantor Fitzgerald assumed coverage on Metsera in a report on Tuesday, February 25th. They set an “overweight” rating for the company. Evercore ISI began coverage on shares of Metsera in a research note on Tuesday, February 25th. They set an “outperform” rating for the company. Guggenheim began coverage on shares of Metsera in a research note on Tuesday, February 25th. They issued a “buy” rating and a $56.00 price objective on the stock. Finally, Bank of America initiated coverage on shares of Metsera in a research report on Tuesday, February 25th. They set a “buy” rating and a $38.00 target price for the company.

About Metsera

Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.